ClinicalTrials.gg

Program

TNX-103

A development code.

Its studies are mostly in Heart Failure · Hypertension, Pulmonary, led by Tenax Therapeutics.

Furthest: phase 3, since Aug 1, 20233 company-led studies, 3 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tenax Therapeutics33 open or runningphase 3since Aug 1, 2023Aug 1, 2023Jun 30, 2028phase 3 · NCT07288398

Also a collaborator on its studies: medpace-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 1, 2023First study: phase 3 study in Hypertension, PulmonaryFirst studyNCT05983250 · 230 enrolled · United States, Canada
  2. Dec 15, 2025Phase 3 study in Heart FailureNCT07288398 · 540 enrolled · United States, Argentina, Austria and more
  3. Feb 20, 2026Phase 3 study in Heart FailureNCT07436689 · 800 planned · United States

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Heart FailureNCT07288398
  2. Mar 2029Primary completion: phase 3 study in Heart FailureNCT07436689

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07436689Heart Failure · United States3By invitationMar 2029800
NCT07288398Heart Failure · United States, Argentina, Austria and more3Active, not recruitingJun 30, 2028540
NCT05983250Hypertension, Pulmonary · United States, Canada3Active, not recruitingJun 30, 2026230

How it is read

Names in the registry

  • “TNX-103”, 3 entries

Codes read as this program: TNX103.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.